Efficacy and safety of first-line chemotherapy plus bevacizumab in patients with metastatic colorectal cancer: A meta-analysis

Chinese Medical Journal

Volumn 127, Issue 3, 2014, Pages 538-546

  Wang, Ming ^a   Zheng, Xiao Feng ^a   Ruan, Xiao Jiao ^a   Ye, Bai Liang ^a   Cai, Long ^a   Lin, Fei Zhuan ^a   Tu, Jin Fu ^a   Jiang, Fei Zhao ^a   Li, Shao Tang ^a  

^a THE FIRST AFFILIATED HOSPITAL OF WENZHOU MEDICAL UNIVERSITY   (China)

Author keywords

Antiangiogenesis; Bevacizumab; First line chemotherapy; Meta analysis; Metastatic colorectal cancer

Indexed keywords

BEVACIZUMAB; CAPECITABINE; FLUOROURACIL; FOLINIC ACID; IRINOTECAN; OXALIPLATIN; PLACEBO; VASCULOTROPIN; ANGIOGENESIS INHIBITOR; MONOCLONAL ANTIBODY;

ARTICLE; BLEEDING; CANCER CHEMOTHERAPY; DIARRHEA; DIGESTIVE SYSTEM PERFORATION; DRUG EFFICACY; DRUG SAFETY; HUMAN; HYPERTENSION; LEUKOPENIA; META ANALYSIS; METASTATIC COLORECTAL CANCER; OVERALL SURVIVAL; PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); PROGRESSION FREE SURVIVAL; PROTEINURIA; RANDOMIZED CONTROLLED TRIAL (TOPIC); THROMBOSIS; WOUND HEALING IMPAIRMENT; COLORECTAL NEOPLASMS; RISK;

ANGIOGENESIS INHIBITORS; ANTIBODIES, MONOCLONAL, HUMANIZED; COLORECTAL NEOPLASMS; HUMANS; ODDS RATIO;

EID: 84893034750     PISSN: 03666999     EISSN: None     Source Type: Journal    
DOI: 10.3760/cma.j.issn.0366-6999.20132241     Document Type: Article

References (60)

1. Siegel R, Naishadham D, Jemal A. Cancer statistics, 2013. CA Cancer J Clin 2013; 63: 11-30.
2. Takayama T, Miyanishi K, Hayashi T, Sato Y, Niitsu Y. Colorectal cancer: genetics of development and metastasis. J Gastroenterol 2006; 41: 185-192.
3. Petrelli N, Douglass HO Jr, Herrera L, Russell D, Stablein DM, Bruckner HW, et al. The modulation of fluorouracil with leucovor in metastatic colorectal carcinoma: a prospective randomized phase III trial. Gastrointestinal Tumor Study Group. J Clin Oncol 1989; 7: 1419-1426.
4. Poon MA, O'Connell MJ, Moertel CG, Wieand HS, Cullinan SA, Everson LK, et al. Biochemical modulation of fluorouracil: evidence of significant improvement of survival and quality of life in patients with advanced colorectal carcinoma. J Clin Oncol 1989; 7: 1407-1418.
5. Piedbois P, Buyse M, Rustum Y, Machover D, Erlichman C, Carlson RW, et al. Modulation of fluorouracil by leucovorin in patients with advanced colorectal cancer: evidence in terms of response rate. Advanced Colorectal Cancer Meta-Analysis Project. J Clin Oncol 1992; 10: 896-903.
6. Goldberg RM, Sargent DJ, Morton RF, Fuchs CS, Ramanathan RK, Williamson SK, et al. A randomized controlled trial of fluorouracil plus leucovorin, irinotecan, and oxaliplatin combinations in patients with previously untreated metastatic colorectal cancer. J Clin Oncol 2004; 22: 23-30.
7. Grothey A, Sargent D. Overall survival of patients with advanced colorectal cancer correlates with availability of fluorouracil, irinotecan, and oxaliplatin regardless of whether doublet or single-agent therapy is used first line. J Clin Oncol 2005; 23: 9441-9442.
8. Rosen LS. Inhibitors of the vascular endothelial growth factor receptor. Hematol Oncol Clin North Am 2002; 16: 1173-1187.
9. Hicklin DJ, Ellis LM. Role of the vascular endothelial growth factor pathway in tumor growth and angiogenesis. J Clin Oncol 2005; 23: 1011-1027.
10. Jain RK, Duda DG, Clark JW, Loeffler JS. Lessons from phase III clinical trials on anti-VEGF therapy for cancer. Nat Clin Pract Oncol 2006; 3: 24-40.
11. Manzoni M, Rovati B, Ronzoni M, Loupakis F, Mariucci S, Ricci V, et al. Immunological effects of bevacizumab-based treatment in metastatic colorectal cancer. Oncology 2010; 79: 187-196.
12. Giantonio BJ, Catalano PJ, Meropol NJ, O'Dwyer PJ, Mitchell EP, Alberts SR, et al. Bevacizumab in combination with oxaliplatin, fluorouracil, and leucovorin (FOLFOX4) for previously treated metastatic colorectal cancer: results from the Eastern Cooperative Oncology Group Study E3200. J Clin Oncol 2007; 25: 1539-1544.
13. Kabbinavar F, Hurwitz HI, Fehrenbacher L, Meropol NJ, Novotny WF, Lieberman G, et al. Phase II, randomized trial comparing bevacizumab plus fluorouracil (FU)/leucovorin (LV) with FU/LV alone in patients with metastatic colorectal cancer. J Clin Oncol 2003; 21: 60-65.
14. Hurwitz H, Fehrenbacher L, Novotny W, Cartwright T, Hainsworth J, Heim W, et al. Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer. N Engl J Med 2004; 350: 2335-2342.
15. Hurwitz HI, Fehrenbacher L, Hainsworth JD, Heim W, Berlin J, Holmgren E, et al. Bevacizumab in combination with fluorouracil and leucovorin: an active regimen for first-line metastatic colorectal cancer. J Clin Oncol 2005; 23: 3502-3508.
16. Giantoni BJ, Levy DE, O'Dwyer PJ, Meropol NJ, Catalano PJ, Benson AB. A phase II study of high-dose bevacizumab in combination with irinotecan, 5-fluorouracil, leucovorin, as initial therapy for advanced colorectal cancer: results from the Eastern Cooperative Oncology Group study E2200. Ann Oncol 2006; 17: 1399-1403.
17. Bir A, Tan W, Wilding GE, Lombardo J, Fakih MG. 5-fluorouracil, leucovorin and oxaliplatin plus bevacizumab in the first-line treatment of metastatic colorectal cancer: a singleinstitute study. Oncology 2007; 72: 4-9.
18. Saltz LB, Clarke S, Diaz-Rubio E, Scheithauer W, Figer A, Wong R, et al. Bevacizumab in combination with oxaliplatinbased chemotherapy as first-line therapy in metastatic colorectal cancer: a randomized phase III study. J Clin Oncol 2008; 26: 2013-2019.
19. Hochster HS, Hart LL, Ramanathan RK, Childs BH, Hainsworth JD, Cohn AL, et al. Safety and efficacy of oxaliplatin and fluoropyrimidine regimens with or without bevacizumab as first-line treatment of metastatic colorectal cancer: results of the TREE study. J Clin Oncol 2008; 26: 3523-3529.
20. Grothey A, Sugrue MM, Purdie Dm, Dong W, Sargent D, Hedrick E, et al. Bevacizumab beyond first progression is associated with prolonged overall survival in metastatic colorectal cancer: results from a large observational cohort study (BRiTE). J Clin Oncol 2008; 26: 5326-5334.
21. Moehler M, Sprinzl MF, Abdelfattah M, Schimanski CC, Adami B, Godderz W, et al. Capecitabine and irinotecan with and without bevacizumab for advanced colorectal cancer patients. World J Gastroenterol 2009; 15: 449-456.
22. Sobrero A, Ackland S, Clarke S, Perez-Carrión R, Chiara S, Gapski J, et al. Phase IV study of bevacizumab in combination with infusional fluorouracil, leucovorin and irinotecan (FOLFIRI) in first-line metastatic colorectal cancer. Oncology 2009; 77: 113-119.
23. Van Cutsem E, Rivera F, Berry S, Kretzschmar A, Michael M, DiBartolomeo M, et al. Safety and efficacy of firstline bevacizumab with FOLFOX, XELO X, FOLFIRI and fluoropyrimidines in metastatic colorectal cancer: the BEAT study. Ann Oncol 2009; 20: 1842-1847.
24. Tebbutt NC, Wilson K, Gebski VJ, Cummins MM, Zannino D, van Hazel GA, et al. Capecitabine, bevacizumab, and mitomycin in first-line treatment of metastatic colorectal cancer: results of the Australasian Gastrointestinal Trials Group randomized phase III MAX study. J Clin Oncol 2010; 28: 3191-3198.
25. Guan ZZ, Xu JM, Luo RC, Feng FY, Wang LW, Shen L, et al. Efficacy and safety of bevacizumab plus chemotherapy in Chinese patients with metastatic colorectal cancer: a randomized phase III ARTIST trial. Chin J Cancer 2011; 30: 682-689.
26. Yoshida M, Goto M, Kii T, Nishitani H, Kawabe S, Kuwakado S, et al. Retrospective study as first-line chemotherapy combined anti-VEGF antibody with fluoropyrimidine for frail patients with unresectable or metastatic colorectal cancer. Digestion 2013; 87: 59-64.
27. Saltz LB, Cox JV, Blanke C, Rosen LS, Fehrenbacher L, Moore MJ, et al. Irinotecan plus fluorouracil and leucovorin for metastatic colorectal cancer. Irinotecan study group. N Engl J Med 2000; 13: 905-914.
28. Stathopoulos GP, Batziou C, Trafalis D, Koutantos J, Batzios S, Stathopoulos J, et al. Treatment of colorectal cancer with and without bevacizumab: a phase III study. Oncology 2010; 78: 376-381.
29. Scappaticci FA, Skillings JR, Holden SN, Gerber HP, Miller K, Kabbinavar F, et al. Arterial thromboembolic events in patients with metastatic carcinoma treated with chemotherapy and bevacizumab. J Natl Cancer Inst 2007; 99: 1232-1239.
30. Nalluri SR, Chu D, Keresztes R, Zhu X, Wu S. Risk of venous thromboembolism with the angiogenesis inhibitor bevacizumab in cancer patients: a meta-analysis. JAMA 2008; 300: 2277-2285.
31. Rafailidis PI, Kakisi OK, Vardakas K, Falagas ME. Infectious complications of monoclonal antibodies used in cancer therapy: a systematic review of the evidence from randomized controlled trials. Cancer 2007; 109: 2182-2189.
32. Saif MW, Elfiky A, Salem RR. Gastrointestinal perforation due to bevacizumab in colorectal cancer. Ann Surg Oncol 2007; 14: 1860-1869.
33. Jadad AR, Moore RA, Carroll D, Jenkinson C, Reynolds DJ, Gavaghan DJ, et al. Assessing the quality of reports of randomized clinical trials: is blinding necessary? Control Clin Trials 1996; 17: 1-12.
34. Kjaergard LL, Villumsen J, Gluud C. Reported methodologic quality and discrepancies between large and small randomized trials in meta-analyses. Ann Intern Med 2001; 135: 982-989.
35. Moher D, Pham B, Jones A, Cook DJ, Jadad AR, Moher M, et al. Does quality of reports of randomised trials affect estimates of intervention efficacy reported in meta-analyses? Lancet 1998; 352: 609-613.
36. Higgins JP, Thompson SG. Quantifying heterogeneity in a metaanalysis. Stat Med 2002; 21: 1539-1558.
37. Higgins JP, Thompson SG, Deeks JJ, Altman DG. Measuring inconsistency in meta-analyses. BMJ 2003; 327: 557-560.
38. DerSimonian R, Laird N. Meta-analysis in clinical trials. Control Clin Trials 1986; 7: 177-188.
39. Mantel N, Haenszel W. Statistical aspects of the analysis of data from retrospective studies of disease. J Natl Cancer Inst 1959; 22: 719-748.
40. Johnson RK, Ringland C, Stokes JB, Anthony MD, Freemantle N, Irs A, et al. Response rate or time to progression as predictors of survival in trials of mCRC or non-small-cell lung cancer: a meta-analysis. Lancet Oncol 2006; 7: 741-746.
41. Cao YF, Tan AH, Gao F, Liu LD, Liao C, Mo ZN. A meta-analysis of randomized controlled trials comparing chemotherapy plus bevacizumab with chemotherapy alone in metastatic colorectal cancer. Int J Colorectal Dis 2009; 24: 677-685.
42. Kabbinavar FF, Schulz J, McCleod M, Patel T, Hamm JT, Hecht JR, et al. Addition of Bevacizumab to Bolus Fluorouracil and Leucovorin in first-line MCRC: results of a randomized phase II trial. J Clin Oncol 2005; 23: 3697-3705.
43. Nexavar (sorafenib) prescribing information. Onyx Pharmaceuticals, Eeryville, CA. (Available at http://www. nexavar.co.uk/pi.htm.)
44. Sutent (sunitinib malate) prescribing information. Pfizer, New York, NY. (Available at https://www.pfizeroncology.com/product-info/sutent-description.jsp?setShowOn=../productinfo/product-centers.jsp&setShowHighlightOn=../product-info/sutent-indication.jsp.)
45. Zhang CJ, Zhao PJ, Li XS, Zhao J, Huang LH, Song Y, et al, Evaluation of efficacy and safety of sunitinib regimen in 22 patients with metastatic renal cell carcinoma: at least 12-month follow-up. Chin Med J 2013; 126: 2826-2829.
46. Dupont J, Schwartz L, Koutcher J, Spriggs D, Gordon M, Mendelson D, et al. Phase I and pharmacokinetic study of VEGF Trap administered subcutaneously to patients with advanced solid malignancies. J Clin Oncol 2004; 22: 197, (abstract 3009).
47. Gordon MS, Cunningham D. Managing patients treated with bevacizumab combination therapy. Oncology 2005; 69: 25-33.
48. Rosen L, Kurzrock R, Jackson E, Wathen L, Parson M, Eschenberg M, et al. Safety and pharmacokinetics of AMG 706 in patients with advanced solid tumors. J Clin Oncol 2005; 23: 195s, (abstract 3013).
49. Morris C, Jurgensmeier J, Robertson J, Hollis S, puchaiski T, Young H, et al. AZD2171, an oral, highly potent, and reversible inhibitor of VEGFR, signaling with potential for the treatment of advanced colorectal cancer. Presented at 2006 Gastrointestinal Cancers Symposium of the American Society of Clinical Oncology, San Francisco, CA, January 28-30, Abstract 242.
50. Syrigos KN, Karapanagiotou E, Boura P, Manegold C, Harrington K. Bevacizumab-Induced Hypertension: Pathogenesis and Management. Biodrugs 2011; 25: 159-169.
51. Lankhorst S, Kappers MH, van Esch JH, Danser AH, van den Meiracker AH. Hypertension during vascular endothelial growth factor inhibition: focus on nitric oxide, endothelin-1, and oxidative stress. Antioxid Redox Signal 2013; 0: 1-11.
52. Miller KD, Chap LI, Holmes FA, Cobleigh MA, Marcom PK, Fehrenbacher L, et al. Randomized phase III trial of capecitabine compared with bevacizumab plus capecitabine in patients with previously treated metastatic breast cancer. J Clin Oncol 2005; 23: 792-799.
53. Miller KD, Wang M, Gralow J, Dickler M, Cobleigh MA, Perez EA, et al. A randomized phase III trial of paclitaxel versus paclitaxel plus bevacizumab as first-line therapy for locally recurrent or metastatic breast cancer: a trial coordinated by the Eastern Cooperative Oncology Group (E2100). Breast Cancer Res Treat 2005; 94: S6, (abstract 3).
54. Sandler AB, Gray R, Brahmer J, Dowlati A, Schiller JH, Perry MC, et al. Randomized phase II/III trial of paclitaxel (P) plus carboplatin (C) with or without bevacizumab (NSC #704865) in patients with advanced non-squamous non-small cell lung cancer (NSCLC): an Eastern Cooperative Oncology Group (ECOG) Trial-E4599. J Clin Oncol 2005; 23: no. 16 suppl LBA4.
55. Scartozzi M, Galizia E, Chiorrini S, Giampieri R, Berardi R, Pierantoni C, et al. Arterial hypertension correlates with clinical outcome in colorectal cancer patients treated with first-line bevacizumab. Annal Oncol 2009; 20: 227-230.
56. De Stefano A, Carlomagno C, Pepe S, Bianco R, De Placido S. Bevacizumab-related arterial hypertension as a predictive marker in metastatic colorectal cancer patients. Cancer Chemother Pharmacol 2011; 68: 1207-1213.
57. Wu SH, Kim C, Baer L, Zhu X. Bevacizumab increases risk for severe proteinuria in cancer patients. J Am Soc Nephrol 2010; 21: 1381-1389.
58. Gordon MS, Cunningham D. Managing patients treated with bevacizumab combination therapy. Oncology 2005; 69: 25-33.
59. Avastin (bevacizumab) prescribing information. Genentech, South San Francisco, CA. (Accessed at http://www.cptech.org/ip/health/avastin.html.)
60. Trikalinos TA, Ioannidis JP. Predictive modeling and heterogeneity of baseline risk in meta-analysis of individual patient data. J Clin Epidemiol 2001; 54: 245-252.